Dry eye disease clearly becomes more common with age in women; in a study of nearly 40,000 US women, prevalence rose from 5.7% under age 50 to 9.8% at 75 and older.

Here's the counterintuitive part: in a very large study of over 25,000 postmenopausal women, those using estrogen-alone hormone therapy actually had a higher rate of dry eye than never-users, not a lower one, with the risk rising the longer they'd used it. This runs against the simple assumption that low estrogen causes dry eye, so estrogen should fix it. Current understanding holds that androgens, not estrogen, may be the main support for the glands that keep the eye's surface lubricated, so if you're on hormone therapy and develop new dry eye, it's reasonable to ask whether the therapy itself could be a contributing factor rather than assuming it will help.

What to know about this answer

This is the sharpest example in the whole knowledge base of the assumption 'low estrogen causes a symptom, so estrogen therapy should fix it' actually failing a direct test: the largest dataset shows the opposite direction of effect.

What the research shows, and which source each finding rests on

In 39,876 US women, prevalence of clinically diagnosed dry eye or severe symptoms rose from 5.7% under age 50 to 9.8% at 75+, an estimated 3.2 million affected US women 50 and older.

B[1]

In 25,665 postmenopausal women of the Women's Health Study, estrogen-alone users had OR 1.69 (95% CI 1.49-1.91) and estrogen-plus-progestin users OR 1.29 (1.13-1.48) for dry eye syndrome versus never-users, with a 15% risk elevation per 3 years of use.

C[2]

The TFOS DEWS II Sex, Gender, and Hormones report documents sex-steroid regulation of the ocular surface, with androgens, estrogens and their receptors present in the lacrimal and meibomian glands.

E[3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Estrogen deficiency causes dry eye; therapy helps

Heather Hirsch, MD and Kelly Casperson, MD, clinical practice

Dry eye spikes in midlife women, and clinicians see it resolve on hormone therapy in individual patients, supporting a straightforward estrogen-deficiency explanation.

Androgen hypothesis; estrogen therapy may worsen dry eye

TFOS DEWS II report; the Women's Health Study data

The largest available dataset shows estrogen therapy, especially unopposed estrogen, is associated with MORE dry eye, not less; androgens are thought to be the main trophic support of the meibomian and lacrimal glands, so estrogen's net effect on the ocular surface may be negative in some tissues.

C[2]E[3]

What would settle it: Randomized trials with objective ocular-surface endpoints, comparing hormone formulation and route (oral versus transdermal, with and without progestogen) plus androgen-arm studies, would resolve the contradiction; until then, the correct counseling is that systemic estrogen therapy is not an evidence-based dry eye treatment and may worsen it.

What is really going on here

  1. Dry eyes on hormone therapy: could my therapy be contributing?
  2. Dry eyes plus dry mouth: should I be screened for Sjogren-type autoimmunity?

Questions for your doctor

  1. Could my current hormone therapy be contributing to my dry eyes rather than helping them?
  2. If I also have dry mouth, should we screen for Sjogren-type autoimmune disease?
  3. What non-hormonal options exist for dry eye relief?
  4. Does the route of hormone therapy (oral versus transdermal) matter for this particular symptom?

Questions with no answer yet

If androgens, not estrogen, are the main trophic support for the glands that keep the eye lubricated, would adding an androgen component to hormone therapy, or using testosterone specifically, actually improve dry eye, given that estrogen alone appears to make it worse?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: This is exactly the kind of study called for: randomized trials with objective ocular-surface endpoints by hormone formulation and route, plus androgen-arm studies specifically, which do not currently exist.

What would test it: A randomized trial testing an androgen-containing arm against standard estrogen therapy, using objective ocular-surface endpoints.

Does the route of hormone delivery, oral versus transdermal, change whether estrogen worsens or helps dry eye, given that the large dataset showing harm used oral hormone therapy specifically?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The large cohort showing increased dry eye risk measured oral estrogen-alone and estrogen-plus-progestin use, and testing by route, oral versus transdermal, with and without progestogen, is explicitly named as what would settle this, which has not been done.

What would test it: A randomized or well-controlled observational study directly comparing oral and transdermal hormone therapy routes against objective dry eye outcomes.

For the specific patients whose dry eyes resolved on hormone therapy in individual clinical accounts, despite the population-level data pointing the opposite direction, is there something different about their eye biology or hormone therapy formulation that explains why they responded differently from the average woman in the large cohort?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: An individual clinical account of resolution on hormone therapy is explicitly juxtaposed against the large cohort's opposite average direction, described as exactly why this remains a genuine, unresolved debate rather than a settled contradiction, without a study explaining the individual-level divergence.

What would test it: A study identifying whether formulation, dose, route, or individual patient characteristics predict which women experience improvement versus worsening of dry eye on hormone therapy.

Sources

  1. 1.Prevalence of dry eye syndrome among US women.Schaumberg DA, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136(2):318-26 · Randomised trial
  2. 2.Hormone replacement therapy and dry eye syndrome.Schaumberg DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA 2001;286(17):2114-9 · Observational study
  3. 3.TFOS DEWS II Sex, Gender, and Hormones Report.Sullivan DA, et al. TFOS DEWS II Sex, Gender, and Hormones Report. Ocul Surf 2017;15(3):284-333 · Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides